Paris, France 2 May 2022 – Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialisation company, today announces approval of Cuvrior™, a new salt of trientine…Original Article
FDA Approves Cuvrior (trientine tetrahydrochloride) for the Treatment of Wilson’s disease
